

Levamisole, Aminorex, and Pulmonary Arterial Hypertension: A Review

Steven B. Karch,^{1,*} Fabio Vaiano,² and Elisabetta Bertol²

¹Consultant Pathologist/Toxicologist, Berkeley, California, USA

²Department of Health Sciences, Forensic Toxicology Division, University of Florence, Florence, Italy

*Corresponding author: Steven B. Karch, Consultant Pathologist/Toxicologist, Berkeley, California, USA. Tel: +1-5108490923, E-mail: skarch@sonic.net

Received: March 5, 2015; Revised: April 8, 2015; Accepted: April 22, 2015

Context: An epidemic of aminorex-associated pulmonary arterial hypertension (PAH), resulting in multiple fatalities, occurred in the 1970s ending only after the drug was removed from the market. In 2009, when it was found that horses de-wormed with the anthelmintic levamisole, metabolized that drug to aminorex, the same drug that caused the 1970s outbreak of PAH. The discovery would not have been cause for concern except to horseracing enthusiasts, who feared horse doping. However, at about the same time the relationship between levamisole and aminorex was discovered, cocaine cartels began adulterating cocaine with levamisole. The rationale for adulterating cocaine with levamisole remains to be established. The purpose of this short review article is to discuss possible reasons for levamisole contamination, new discoveries about the human pharmacokinetics of aminorex, and the possible relationship between aminorex and pulmonary arterial hypertension in man.

Evidence acquisition: Medline contents, as well as estimates published by the U.S. drug enforcement agency (DEA), US state department, and the European monitoring center for drugs and drug abuse (EMCDDA) were reviewed and relevant articles retrieved. There is uniform agreement among the various monitoring agencies analyzed.

Results: Approximately 70 percent of the U.S. cocaine supply and 40 percent of the European cocaine supply is contaminated with levamisole. Aminorex has the same binding affinities for serotonin and other neurotransmitters as amphetamine. As serotonin is considered to be an important factor in the development of PAH, the possibility of another epidemic of aminorex-induced PAH, this time among cocaine abusers, seems real, and threatening.

Conclusions: The results of the first human pharmacokinetic studies of aminorex were first characterized in 2013. The results suggest that while humans could produce aminorex from levamisole, they probably do not convert very much. Even though cases of PAH have been reported in cocaine users, the latest pharmacokinetic studies suggest that very little aminorex is actually produced from the ingested levamisole, probably not enough to cause PAH. However, since both cocaine and aminorex can cause PAH the situation remains unclear. The lack of a clear answer is partially the development of an insidious pulmonary hypertension, producing subtle and non-specific symptoms in its early stages.

Keywords: Levamisole; Aminorex; Cocaine; Amphetamine; Serotonin; Bone Morphogenetic Protein

1. Context

The pressure in normal human pulmonary arteries varies between 8 and 20 mmHg at rest, and may reach 30 mmHg or more during physical activity. Pulmonary artery pressures greater than 25 mmHg at rest are considered pathological. Under older classifications, pressures over 30 mmHg during exercise were considered abnormal, but that assumption has been proven incorrect and accordingly dropped from the world health organization's (WHO) classification of pulmonary hypertension, which is now based on the etiology of hypertension. Five broad categories of pulmonary hypertension are recognized. Group I constitutes the largest category, and it is the only category where plexiform (a characteristic vascular change of pulmonary arteries in pulmonary hypertension) lesions, are seen (1). The other conditions in Group I are shown in Box 1. Many of the disorders that comprise this class, such as connective tissues like scleroderma, infectious diseases like HIV, and congenital heart disease will be familiar. However, the connection with

drugs and toxins is often overlooked and poorly understood.

Box 1. Types of Pulmonary Arterial Hypertension, Group I^a

Pulmonary Arterial Hypertension
Idiopathic
Heritable
Drugs and toxins induced
Associated with
a. Connective tissue disorders
b. HIV infection
c. Portal hypertension
d. Congenital heart disease
e. Schistosomiasis
f. Chronic hemolytic anemic
Persistent pulmonary hypertension of the newborn
Pulmonary veno-occlusive disease/ pulmonary capillary hemangiomatosis

^a Adopted from the current world health organization criteria.

norex. However, elsewhere in the body, levamisole exerts toxicity in its own right. Users of levamisole-adulterated cocaine users are presenting at emergency rooms in increasing numbers. Three disorders, which in the past were relatively uncommon and almost unheard of in drug users have become very common: agranulocytosis, ANCA necrotizing vasculitis, and cutaneous necrosis (24-26). As aminorex is a known cause of pulmonary hypertension (27, 28), one might expect an increase in cases of pulmonary hypertension as well, but that has not proven to be the case.

Based on clinical studies of patients presenting for emergency room care, it can be estimated that an average symptomatic cocaine user has consumed more than a gram of cocaine per day. If the cocaine consumed actually contained 10 percent levamisole, roughly 100 mg of levamisole would have also been ingested. The result of this calculation is disturbing and perplexing because, among those who died during the aminorex epidemic of the late 1960s and early 1970s, the average patient was consuming far less than 100 mg of aminorex per day. The explanation is simple: humans simply do not metabolize very much levamisole to aminorex. Even if a heavy cocaine user consumed 8-10 grams of levamisole-contaminated cocaine per day, and they do (29), they still would only be ingesting trivial amounts of aminorex, simply because the conversion rate of levamisole is so low (15).

Elevations in plasma 5-HT (serotonin) have been implicated in the pathogenesis of both cardiac and pulmonary disease in methamphetamine abusers. Under normal circumstances, plasma 5-HT concentrations are kept at low levels by transporter-mediated uptake of 5-HT into platelets, and also by metabolism to form 5-hydroxyindoleacetic acid (5-HIAA). Many abused drugs, including amphetamines, target 5-HT transporters and, indirectly, increase the amount of circulating 5-HT. Animal studies have shown that drugs like amphetamine, methamphetamine, and aminorex, raise 5-HT levels sufficiently to initiate mitogenesis in pulmonary artery smooth muscle cells, thereby activating the signaling cascade that ultimately leads to PAH (30) and ultimately the same histological changes seen in man (31). Mounting evidence indicates that elevated 5-HT concentrations also account for the smooth muscle hypertrophy that is always evident in the hearts of chronic stimulant abusers (32).

Type I pulmonary arterial hypertension is characterized by the formation of plexiform and concentric lesions composed of proliferative vascular cells. As the process advances, there is increased pulmonary vascular resistance, leading to right ventricular failure and, if left untreated, ultimately death. In experimental animals, when PAH occurs, intimal and medial hypertrophy of the precapillary pulmonary vascular system occurs. Ultimately, these changes lead to vessel obliteration, in situ thrombosis, and plexiform lesions that, taken together, constitute the primary lesions of PAH.

The confluence of all these changes is referred to as

vascular remodeling, and the etiology is clearly multifactorial. The most consistent finding in PAH is medial hypertrophy, a consequence of some, as yet uncharacterized, abnormality within the pulmonary artery smooth muscle cells themselves. The details of this process are far too complex for this short review, but genetic studies point to the involvement of bone morphogenetic protein (BMP) receptor type II gene (BMPR2). Somehow, mutation in the BMPR2 gene controls and/or initiates the vascular remodeling process within the pulmonary vasculature. At the moment, attention is focused on the upstream role of microRNAs (33) (which control more than 60% of the human genome (34)). These microRNAs act as posttranscriptional regulators for the expression of BMPR2.

Much of what we know about aminorex we learned from an outbreak of aminorex poisoning that occurred in 1967, not long after aminorex first became available on the commercial market in Austria, Switzerland, and West Germany. In January 1971, a brief report in the British medical journal described the sudden occurrence of a particularly virulent form of pulmonary hypertension. The etiology was undetermined, but the common denominator in all of these patients was the prolonged use of the new anorectic drug, aminorex fumarate.

The first cases of aminorex poisoning were reported six to 12 months after aminorex fumarate (sold under the brand names Minocel and Apiquel) came to market (35). The average dose per day ingested by the affected patients (mostly women) ranged from 14 to 42 mg/day; the average patient had been taking the drug for more than one year (28). A Swiss researcher reported that in 1968 alone, the number of patients presenting with pulmonary hypertension had increased 10- to 20-fold (36).

At the time of this outbreak, the science of pharmacokinetics was in its infancy, and very little was known about aminorex, even after it came to market. Now, thanks to the work of German researchers a good deal more is known. After giving 100 mg doses of levamisole to native volunteers, standard pharmacokinetics studies were performed (Table 1). Levamisole could be detected in serum for up to 36 hours after ingestion, as could aminorex, but at no time did aminorex concentrations ever exceed the limit of quantification (LOQ). Levamisole kinetics are best described by a one-compartment model. The following parameters were calculated: $k_a = 1.2$ [1/h], $CL/F = 52$ l/h, $V/F = 347$ l, f (renal) = 0.0005, $t_{1/2} = 2.0$ h, $AUC = 1923$ ng/mL*h, $c_{max} = 214$ ng/mL, $t_{max} = 1.98$ h [15]. Interestingly, it was also found that levamisole could be quantified in 42.5 percent of cocaine-positive plasma samples (range 2.2 to 224 ng/mL), but that aminorex was positive in only 11.3% of the cases and, as indicated above, never at levels higher than the LOQ (Table 1). Some have suggested that given that the half-life of aminorex is longer than that of cocaine, the intent of adulteration may be to prolong the "high" associated with cocaine use, and now that the pharmacokinetics of levamisole have been elucidated, the suggestion seems plausible.

Table 1. Human Pharmacokinetics of Levamisole ^a

Parameters	Value
ka	1.2 [1.2 h]
CL/F	52/L/h
VF	347.1
f (renal)	0.0005
t_{1/2}	2.0 h
cm_{as}	214 ng/mL
AUC	1923 ng/mL*h
Tmax	1.98

^a Adopted from Hess et al. (15, 37).

4. Conclusions

The final verdict on cocaine/levamisole/aminorex and PAHs is still not in and should be investigated more. One confounding factor is that the diagnosis of PAH is notoriously difficult to make, and even when the diagnosis is made, it is usually delayed. Based on the epidemic of the 1970s, it would appear that, on average, daily ingestion of aminorex for at least a year is required. Mostly, PAH patients complain of exercise intolerance, chest pain, and shortness of breath. None of these symptoms are very specific. These are exactly the same complaints expressed by patients with left heart disease, or other types of lung disease; they also happen to be the most common causes of PAH (14). Based on the dosages reported in the 1970s, only severely addicted cocaine abusers would seem to ingest enough levamisole to be at risk. Given these limitations, concerns about a cocaine/aminorex induced epidemic are not very great. With this study we tried to chart a course towards a real understanding on PAH risk in cocaine addicted, hoping that new studies will be performed. Only time will tell.

Authors' Contributions

Study concept and design: Steven B. Karch; acquisition of literature data: Steven B. Karch; analysis and interpretation of literature data: Steven B. Karch and Elisabetta Bertol; drafting of the manuscript: Steven B. Karch, Elisabetta Bertol, and Fabio Vaiano; critical revision of the manuscript for important intellectual content: Steven B. Karch and Elisabetta Bertol; administrative, technical, and material support: Steven B. Karch, Elisabetta Bertol, and Fabio Vaiano; Study supervision: Steven B. Karch.

References

1. Hoendermis ES. Pulmonary arterial hypertension: an update. *Neth Heart J*. 2011;**19**(12):514–22.
2. Colvin KL, Yeager ME. Animal Models of Pulmonary Hypertension: Matching Disease Mechanisms to Etiology of the Human Disease. *J Pulm Respir Med*. 2014;**4**(4)
3. Ryan J, Dasgupta A, Huston J, Chen KH, Archer SL. Mitochondrial dynamics in pulmonary arterial hypertension. *J Mol Med (Berl)*. 2015;**93**(3):229–42.
4. Liou CM, Tsai SC, Kuo CH, Williams T, Ting H, Lee SD. Chronic

methamphetamine exposure induces cardiac fas-dependent and mitochondria-dependent apoptosis. *Cardiovasc Toxicol*. 2014;**14**(2):134–44.

5. Barbosa DJ, Serrat R, Mirra S, Quevedo M, de Barreda EG, Avila J, et al. The mixture of "ecstasy" and its metabolites impairs mitochondrial fusion/fission equilibrium and trafficking in hippocampal neurons, at in vivo relevant concentrations. *Toxicol Sci*. 2014;**139**(2):407–20.
6. Collazos J, Martinez E, Fernandez A, Mayo J. Acute, reversible pulmonary hypertension associated with cocaine use. *Respir Med*. 1996;**90**(3):171–4.
7. Yakel DJ, Eisenberg MJ. Pulmonary artery hypertension in chronic intravenous cocaine users. *Am Heart J*. 1995;**130**(2):398–9.
8. Cogswell R, Kobashigawa E, McGlothlin D, Shaw R, De Marco T. Validation of the Registry to Evaluate Early and Long-Term Pulmonary Arterial Hypertension Disease Management (REVEAL) pulmonary hypertension prediction model in a unique population and utility in the prediction of long-term survival. *J Heart Lung Transplant*. 2012;**31**(11):1165–70.
9. Galie N, Hoeper MM, Humbert M, Torbicki A, Vachiery JL, Barbera JA, et al. Guidelines for the diagnosis and treatment of pulmonary hypertension: the Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS), endorsed by the International Society of Heart and Lung Transplantation (ISHLT). *Eur Heart J*. 2009;**30**(20):2493–537.
10. Rothman RB, Ayestas MA, Dersch CM, Baumann MH. Aminorex, fenfluramine, and chlorphentermine are serotonin transporter substrates. Implications for primary pulmonary hypertension. *Circulation*. 1999;**100**(8):869–75.
11. Ho EN, Leung DK, Leung GN, Wan TS, Wong AS, Wong CH, et al. Aminorex and rexamino as metabolites of levamisole in the horse. *Anal Chim Acta*. 2009;**638**(1):58–68.
12. Gaine SP, Rubin LJ, Kmetzo JJ, Palevsky HI, Traill TA. Recreational use of aminorex and pulmonary hypertension. *Chest*. 2000;**118**(5):1496–7.
13. Karch SB, Mari F, Bartolini V, Bertol E. Aminorex poisoning in cocaine abusers. *Int J Cardiol*. 2012;**158**(3):344–6.
14. van Riel AC, Schuurin MJ, van Hensen ID, Zwinderman AH, Cozijnsen L, Reichert CL, et al. Contemporary prevalence of pulmonary arterial hypertension in adult congenital heart disease following the updated clinical classification. *Int J Cardiol*. 2014;**174**(2):299–305.
15. Hess C, Ritke N, Broecker S, Madea B, Musshoff F. Metabolism of levamisole and kinetics of levamisole and aminorex in urine by means of LC-QTOF-HRMS and LC-QqQ-MS. *Anal Bioanal Chem*. 2013;**405**(12):4077–88.
16. Karch SB, Defraia B, Messerini L, Mari F, Vaiano F, Bertol E. Aminorex associated with possible idiopathic pulmonary hypertension in a cocaine user. *Forensic Sci Int*. 2014;**240**:e7–10.
17. Anon LO. *National Early Warning System of the Council of Ministers of Italy*. 2009.
18. Casale J, Corbeil E, Hays P. Identification of Levamisole Impurities Found in Illicit Cocaine Exhibits Microgram. 2006;**6**(3-4):2.
19. Bertucci C, Tedesco D, Fabini E, Di Pietra AM, Rossi F, Garagnani M, et al. Determination of levamisole and tetramisole in seized cocaine samples by enantioselective high-performance liquid chromatography and circular dichroism detection. *J Chromatogr A*. 2014;**1363**:150–4.
20. Lapachinske SF, Okai GG, dos Santos A, de Bairos AV, Yonamine M. Analysis of cocaine and its adulterants in drugs for international trafficking seized by the Brazilian Federal Police. *Forensic Sci Int*. 2015;**247**:48–53.
21. US Department of Justice. *National Drug Threat Assessment: 2010*. Washington, DC: National Drug Intelligence Center; 2010.
22. Raymon LP, Isenschmid DS. Letter to the editor: The possible role of levamisole in illicit cocaine preparations. *J Anal Toxicol*. 2009;**33**(9):620–2.
23. Hofmaier T, Luf A, Seddik A, Stockner T, Holy M, Freissmuth M, et al. Aminorex, a metabolite of the cocaine adulterant levamisole, exerts amphetamine like actions at monoamine transporters. *Neurochem Int*. 2014;**73**:32–41.

24. Picazo ML, Martinez Ara J, Diaz C, Perez-Mies B. [Nephropathy with occlusive intracapillary IgA thrombi and necrotizing vasculitis, manifesting as rapidly progressive renal insufficiency]. *Nefrologia*. 2003;**23**(1):27-36.
25. Buchanan JA, Vogel JA, Eberhardt AM. Levamisole-induced occlusive necrotizing vasculitis of the ears after use of cocaine contaminated with levamisole. *J Med Toxicol*. 2011;**7**(1):83-4.
26. Buchanan JA, Oyer RJ, Patel NR, Jacquet GA, Bornikova L, Thienelt C, et al. A confirmed case of agranulocytosis after use of cocaine contaminated with levamisole. *J Med Toxicol*. 2010;**6**(2):160-4.
27. Kew MC. Aminorex fumarate: a double-blind trial and examination for signs of pulmonary arterial hypertension. *S Afr Med J*. 1970;**44**(14):421-3.
28. Follath F, Burkart F, Schweizer W. Drug-induced pulmonary hypertension? *BMJ*. 1971;**1**(5743):265-6.
29. Blaho K, Logan B, Winbery S, Park L, Schwilke E. Blood cocaine and metabolite concentrations, clinical findings, and outcome of patients presenting to an ED. *Am J Emerg Med*. 2000;**18**(5):593-8.
30. Shimoda LA, Laurie SS. Vascular remodeling in pulmonary hypertension. *J Mol Med (Berl)*. 2013;**91**(3):297-309.
31. Herve P, Humbert M, Sitbon O, Parent F, Nunes H, Legal C, et al. Pathobiology of pulmonary hypertension. The role of platelets and thrombosis. *Clin Chest Med*. 2001;**22**(3):451-8.
32. Shannon R, Chaudhry M. Effect of alpha1-adrenergic receptors in cardiac pathophysiology. *Am Heart J*. 2006;**152**(5):842-50.
33. Grant JS, White K, MacLean MR, Baker AH. MicroRNAs in pulmonary arterial remodeling. *Cell Mol Life Sci*. 2013;**70**(23):4479-94.
34. Friedman RC, Burge CB. MicroRNA target finding by comparative genomics. *Methods Mol Biol*. 2014;**1097**:457-76.
35. Gurtner HP. Pulmonary hypertension, "plexogenic pulmonary arteriopathy" and the appetite depressant drug aminorex: post or propter? *Bull Eur Physiopathol Respir*. 1979;**15**(5):897-923.
36. Rivier JL. [Primary arterial pulmonary hypertension. Preliminary statistical results under the sponsorship of the Swiss Cardiological Society and with the aid the Swiss Foundation f Cardiology]. *Schweiz Med Wochenschr*. 1970;**100**(4):143-5.
37. Hess C, Ritke N, Sydow K, Mehling LM, Ruehs H, Madea B, et al. Determination of levamisole, aminorex, and pemoline in plasma by means of liquid chromatography-mass spectrometry and application to a pharmacokinetic study of levamisole. *Drug Test Anal*. 2014;**6**(10):1049-54.